WINDTREE THERAPEUTICS INC /DE/ Operating Lease, Right-of-Use Asset, Amortization Expense
WINDTREE THERAPEUTICS INC /DE/ (WINT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-11-19
- WINDTREE THERAPEUTICS INC /DE/ operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was -$227.00K, a 314.15% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $115.00K, a 10.58% increase year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $112.00K, a 10.89% increase year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $82.00K, a 18.00% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ operating lease, right-of-use asset, amortization expense for fiscal 2024 was $393.00K, a 3.91% decline from fiscal 2023.
- WINDTREE THERAPEUTICS INC /DE/ operating lease, right-of-use asset, amortization expense for fiscal 2023 was $409.00K, a 22.54% decline from fiscal 2022.
- WINDTREE THERAPEUTICS INC /DE/ operating lease, right-of-use asset, amortization expense for fiscal 2022 was $528.00K, a 22.01% decline from fiscal 2021.
- WINDTREE THERAPEUTICS INC /DE/ operating lease, right-of-use asset, amortization expense for fiscal 2021 was $677.00K, a 43.13% increase from fiscal 2020.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$227.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$112.00K derived: sum of 2 quarters · filed 2025-11-19 | $0.00 10-Q · filed 2025-11-19 | $82.00K derived: sum of 4 quarters · filed 2025-11-19 |
| 2025-06-30 | $115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $227.00K 10-Q · filed 2025-08-19 | $309.00K derived: sum of 3 quarters · filed 2025-08-19 | $415.00K derived: sum of 4 quarters · filed 2025-11-19 |
| 2025-03-31 | $112.00K 10-Q · filed 2025-05-15 | $194.00K derived: sum of 2 quarters · filed 2025-05-15 | $300.00K derived: sum of 3 quarters · filed 2025-11-19 | $404.00K derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $188.00K derived: sum of 2 quarters · filed 2025-11-19 | $292.00K derived: sum of 3 quarters · filed 2025-11-19 | $393.00K 10-K · filed 2025-04-15 |
| 2024-09-30 | $106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $210.00K derived: sum of 2 quarters · filed 2025-11-19 | $311.00K 10-Q · filed 2025-11-19 | $411.00K derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $205.00K 10-Q · filed 2025-08-19 | $305.00K derived: sum of 3 quarters · filed 2025-08-19 | $401.00K derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | $101.00K 10-Q · filed 2025-05-15 | $201.00K derived: sum of 2 quarters · filed 2025-05-15 | $297.00K derived: sum of 3 quarters · filed 2025-05-15 | $394.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $196.00K derived: sum of 2 quarters · filed 2025-04-15 | $293.00K derived: sum of 3 quarters · filed 2025-04-15 | $409.00K 10-K · filed 2025-04-15 |
| 2023-09-30 | $96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-26 | $193.00K derived: sum of 2 quarters · filed 2024-11-26 | $309.00K 10-Q · filed 2024-11-26 | $420.00K derived: sum of 4 quarters · filed 2024-11-26 |
| 2023-06-30 | $97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | $213.00K 10-Q · filed 2024-08-19 | $324.00K derived: sum of 3 quarters · filed 2024-08-19 | $434.00K derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | $116.00K 10-Q · filed 2024-05-15 | $227.00K derived: sum of 2 quarters · filed 2024-05-15 | $337.00K derived: sum of 3 quarters · filed 2024-05-15 | $470.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $221.00K derived: sum of 2 quarters · filed 2024-04-16 | $354.00K derived: sum of 3 quarters · filed 2024-04-16 | $528.00K 10-K · filed 2024-04-16 |
| 2022-09-30 | $110.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $243.00K derived: sum of 2 quarters · filed 2023-11-09 | $417.00K 10-Q · filed 2023-11-09 | $589.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $307.00K 10-Q · filed 2023-08-07 | $479.00K derived: sum of 3 quarters · filed 2023-08-07 | $648.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $174.00K 10-Q · filed 2023-05-15 | $346.00K derived: sum of 2 quarters · filed 2023-05-15 | $515.00K derived: sum of 3 quarters · filed 2023-05-15 | $681.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $341.00K derived: sum of 2 quarters · filed 2023-03-31 | $507.00K derived: sum of 3 quarters · filed 2023-03-31 | $677.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $335.00K derived: sum of 2 quarters · filed 2022-11-14 | $505.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $336.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $170.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $473.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |